Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPN14770 in Male Adults With Fragile X Syndrome
NCT05358886Phase 3Completed
- Sponsor
- Tetra Therapeutics
- Start
- Nov 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zatolmilast in Fragile X syndrome (FXS), sponsored by Tetra Therapeutics. Started Nov 2022; status: completed.
02
Drugs
zatolmilast
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT05358886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05358886.